1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Biotechs Benefit From Pharma Deals And Dollars

 
• By Mandy Jackson

Big pharma companies may be under pressure to buy like-sized peers with late-stage clinical programs and marketed products, but several collaborations with and investments in biotechnology firms announced during the first few days of 2016 show that the world's largest drug makers also are focused on long-term prospects for their research and development pipelines.

Big pharma companies may be under pressure to buy like-sized peers with late-stage clinical programs and marketed products, but several collaborations with and investments in biotechnology firms announced during the first few days of 2016 show that the world's largest drug makers also are focused on long-term prospects for their research and development pipelines.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.